Author’s replyBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4282 (Published 10 August 2010) Cite this as: BMJ 2010;341:c4282
- Bruce Arroll, professor and head
- 1Department of General Practice and Primary Health Care, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
We did mention candesartan in table 2, although we did not specifically reference the CHARM studies.1 2 Our focus was on the generalist physician and GP, and in primary care and cardiological care evidence shows that angiotensin converting enzyme (ACE) inhibitors and β blockers are not being initiated or titrated to maximal doses. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial